

Applicant : Antonio Iavarone and Anna Lasorella  
Serial No. : 10/025,170  
Filed : December 18, 2001  
Page 3

Enclosed herewith is a copy of the Notice to File Missing Parts of Nonprovisional Application, as required.

Oath or Declaration

Enclosed is a properly signed declaration in compliance with 37 CFR 1.63. Also enclosed are two Powers of Attorney, one from each of the inventors.

Compliance with Sequence Rules

Enclosed herewith is a paper copy and a computer readable (diskette) form of the sequence listing. The content of the sequence listing information recorded in computer readable form is identical to the written (paper) sequence listing enclosed herewith. The sequence listing presents no new matter. Please enter the sequence listing into the application.

The specification amendments are also provided to refer to the SEQ ID NOs when the sequences are discussed.

Fee payment

Applicants assert small entity status. Accordingly, enclosed herewith is a check for \$522, which encompasses the following fees:

\$370 Basic filing fee

\$ 45 5 excess claims over 20 @ 9 each

\$ 42 1 excess independent claim over 3

\$ 65 Late declaration fee

\$522 Total

Applicant : Antonio Iavarone and Anna Lasorella  
Serial No. : 10/025,170  
Filed : December 18, 2001  
Page 4

Authorization is hereby given to charge any deficiency or credit any overpayment, or charge any additional extension of time fee necessary to preserve the pendency of the subject application to Deposit Account No. 01-1785.


Conclusion

Applicant believes that, with this filing, all preliminary matters are resolved. Applicant therefore requests that this application proceed to examination. If there are any minor matters preventing examination of this case, applicant requests that the PTO contact the undersigned attorney.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 697-5995

Dated: New York, New York  
May 22, 2002

By:   
Elie H. Gendloff  
Registration No.: 44,704



Marked-Up Specification Amendments - U.S. Patent Application No. 10/024,659  
Additions are underlined. There are no deletions.

Paragraph 105, at page 35:

A human genomic library was screened with an *Id2*-specific cDNA probe, and two phage clones were isolated and sequenced. A 3.0-kilobase (kb) *BglI-NheI* fragment was subcloned in pGL3 Basic (Promega) to generate pGId2-2750. The *Id2* reporter plasmid pGId2-1330 was generated by 5' deletion of the larger promoter fragment pGId2-2750. Plasmids pGId2-EcoRI and pGId2-EcoRI $\Delta$  were generated by placing a 900-bp *EcoRI* fragment upstream of a 204-bp minimal *Id2* promoter. All plasmids harbor a 35-bp region downstream of the start site. Site-specific mutagenesis was performed by a PCR-based protocol, and transfections and luciferase assays were done as described (41). Luciferase activity was normalized to the expression of pCMV-LacZ cotransfected as an internal standard. PCR primers used for chromatin immunoprecipitation assays were 5'-TCTGTTCCTACTGTGGCACGTAT-3' (SEQ ID NO:3) (sense) and 5'-CTCGATAATGGGGAACACTGT-3' (SEQ ID NO:4) (antisense). A detailed protocol for chromatin crosslinking, immunoprecipitation, and PCR has been published (31).

Paragraph 137, at page 47:

Phosphorothioate oligonucleotides complementary to human *Id2* and the mismatched control were obtained from Gibco BRL. The sequences of the oligonucleotides were as follows: *Id2*-AS, 5'-AGGCTTTCATGCTGACCGC-3' (SEQ ID NO:5); *Id2*-MSM, 5'-GCGAGTTGTGCGACGGTCT-3' (SEQ ID NO:6). Oligonucleotides were mixed with Superfect (Qiagen) according to the manufacturer's instructions, and were used to treat LAN1 cells at the final concentration of 0.8 M. After incubation for 24 h, cells were analyzed for the ability to incorporate BrdU and form colonies in soft agar.